Sign in
Explore the registryTrack Pembrolizumab 200 mg's trials

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Pembrolizumab 200 mgOngoingActive not recruitingPhase 1Open NCT02861573 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…